Lainate, Italy – October 11, 2007 – Cosmo Pharmaceuticals SpA, (SWX: COPN) announced today an agreement with Ferring Pharmaceuticals for the licensing of Budesonide MMX™. The agreement grants Ferring an exclusive worldwide license (excluding Japan and the USA) for Budesonide MMX™, which is predicted to become the first worldwide approved oral corticosteroid for ulcerative colitis.
